Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):462-7. doi: 10.1016/j.ijrobp.2007.09.056. Epub 2008 Feb 19.


Purpose: To evaluate the efficacy and safety of proton beam therapy (PBT) for patients with hepatocellular carcinoma (HCC) located adjacent to the porta hepatis.

Methods and materials: Subjects of the study were 53 patients with HCC located within 2 cm of the main portal vein. All patients had tumor confined to the radiation field with no evidence of metastatic disease. All patients had hepatic function levels of a Child-Pugh score of 10 or less, Eastern Cooperative Oncology Group performance status of 2 or less, and no uncontrolled ascites. Patients underwent PBT of 72.6 GyE in 22 fractions from Sept 2001 to Dec 2004.

Results: After 3 years, the actuarial survival rate was 45.1% and local control rate was 86.0%. Prognostic factors for survival included Child-Pugh score, number of tumors, and alpha-fetoprotein levels. No late treatment-related toxicity of Grade 2 or higher was observed.

Conclusions: The PBT delivering 72.6 GyE in 22 fractions appears to be effective and safe for HCC adjacent to the porta hepatis.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / blood supply
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / radiotherapy*
  • Female
  • Humans
  • Liver Neoplasms / blood
  • Liver Neoplasms / blood supply
  • Liver Neoplasms / mortality
  • Liver Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Portal Vein*
  • Proton Therapy*
  • Radiotherapy Dosage
  • Survival Rate
  • alpha-Fetoproteins / metabolism


  • alpha-Fetoproteins